FEB 12, 2020 6:52 PM PST

Diabetic Drug Increasces Risk of Heart Complications

WRITTEN BY: Nouran Amin

A drug by the name of ‘rosiglitazone’ used to treat type 2 diabetes was found to be associated with increased risk of heart problems, especially heart failure. Findings were based on a comprehensive evaluation of the cardiovascular risk from rosiglitazone use.

Rosiglitazone belongs to a class of drugs known as thiazolidinediones that help target blood sugar levels in patients with type 2 diabetes, however, it can also increase the risk of heart complications. As a result, Rosiglitazone use was suspended in Europe and holds previous restrictions in the United States.

Researchers stated: "Our study highlights the need for independent evidence assessment to promote transparency and ensure confidence in approved therapeutics, and postmarket surveillance that tracks known and unknown risks and benefits."

Learn more:

But, since 2007, studies reported conflicting findings about whether rosiglitazone does lead to risky heart complications. These studies did not access raw data from patients and mostly were based on summary level data that was not to the highest reliability. The drug maker of rosiglitazone--GlaxoSmithKline (GSK)--has placed effort to make patient data available for investigators and thus prompted researchers to re-analyze uncertainty about the role of the drug in cardiovascular risk.

"Our study suggests that when evaluating drug safety and performing meta-analyses focused on safety, IPD might be necessary to accurately classify all adverse events," noted the researchers. "By including these data in research, patients, clinicians, and researchers would be able to make more informed decisions about the safety of interventions."

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
MAY 19, 2022
Drug Discovery & Development
Repurposed Antibiotic Shows Promise Against COVID-19 in Mice
MAY 19, 2022
Repurposed Antibiotic Shows Promise Against COVID-19 in Mice
An antibiotic known as clofoctol has shown promise in treating SARS-CoV-2 in mice. The corresponding study was published ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 10, 2022
Drug Discovery & Development
The consequences of inappropriate antibiotic prescriptions in children
JUN 10, 2022
The consequences of inappropriate antibiotic prescriptions in children
The discovery of antibiotics in the early 1900’s was one of the most important discoveries in medical history. The ...
JUN 13, 2022
Microbiology
Mucus Contains Fungus-Fighting Molecules
JUN 13, 2022
Mucus Contains Fungus-Fighting Molecules
The human body plays host to a variety of microorganisms, including fungi like Candida albicans. Some strains of Candida ...
JUN 13, 2022
Cancer
Clinical Trial Demonstrates an Amazing 100% Response
JUN 13, 2022
Clinical Trial Demonstrates an Amazing 100% Response
The results of a Clinical Trial for rectal cancer patients published last week in the New England Journal of Medicine co ...
Loading Comments...